These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 22509718)

  • 1. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
    Janssens A; Van Roy N; Poppe B; Noens L; Philippé J; Speleman F; Offner F
    Eur J Haematol; 2012 Jul; 89(1):72-80. PubMed ID: 22509718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
    Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.
    Wawrzyniak E; Kotkowska A; Blonski JZ; Siemieniuk-Rys M; Ziolkowska E; Giannopoulos K; Robak T; Korycka-Wolowiec A
    Eur J Haematol; 2014 Feb; 92(2):91-101. PubMed ID: 24138550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
    Trojani A; Montillo M; Nichelatti M; Tedeschi A; Colombo C; Veronese S; Mura MA; Ricci F; Scarpati B; Colosimo A; Lodola M; Morra E
    Cancer Biomark; 2010; 6(1):1-9. PubMed ID: 20164537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
    Del Giudice I; Davis Z; Matutes E; Osuji N; Parry-Jones N; Morilla A; Brito-Babapulle V; Oscier D; Catovsky D
    Leukemia; 2006 Jul; 20(7):1231-7. PubMed ID: 16642047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
    Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC;
    Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of 5'IGH deletions in B-cell chronic lymphocytic leukemia.
    Quintero-Rivera F; Nooraie F; Rao PN
    Cancer Genet Cytogenet; 2009 Apr; 190(1):33-9. PubMed ID: 19264231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
    Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
    Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
    Hassab AH; Elbordiny MM; Elghandour AH; Sorour AF; Swelem RS
    Egypt J Immunol; 2011; 18(2):77-93. PubMed ID: 23082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
    Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
    Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH.
    Orlandi EM; Bernasconi P; Pascutto C; Giardini I; Cavigliano PM; Boni M; Zibellini S; Cazzola M
    Hematol Oncol; 2013 Sep; 31(3):136-42. PubMed ID: 23060227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal evolution as detected by interphase fluorescence in situ hybridization is associated with worse overall survival in a population-based analysis of patients with chronic lymphocytic leukemia in British Columbia, Canada.
    Huang SJ; Bergin K; Smith AC; Gerrie AS; Bruyere H; Dalal CB; Sugioka DK; Hrynchak M; Ramadan KM; Karsan A; Gillan TL; Toze CL
    Cancer Genet; 2017 Jan; 210():1-8. PubMed ID: 28212806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.